Clinical Characteristics and Outcomes in Young‐Onset Multiple System Atrophy
Movement Disorders Clinical Practice · 2024
DOI: 10.1002/mdc3.13925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Negin Badihian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple System Atrophy, Pure Autonomic Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCATS NIH HHS, FDA HHS.
Abstract (Originalsprache)
Background
Young‐onset multiple system atrophy (YOMSA) is defined as the onset of multiple system atrophy (MSA) before the age of 40 years old. YOMSA is rare and there is much uncertainty of the phenotype and natural history in patients with YOMSA.
Objective
The objective is to evaluate the characteristics and disease course of patients with YOMSA.
Methods
We retrospectively reviewed medical records of patients with MSA who were evaluated at all Mayo Clinic sites from 1998 to 2021. We identified patients with YOMSA and evaluated clinical characteristics, autonomic function testing results, and disease course.
Results
Of 1496 patients with a diagnosis of clinically probable or clinically established MSA, 20 patients had YOMSA. The median age of onset was 39.1 (interquartile range [IQR] = 37.1, 40.1) years; 13 patients (65%) were male. MSA‐parkinsonism was the most common subtype (65%). The median duration of symptom onset to YOMSA diagnosis was 4.9 (IQR = 3.7, 9) years. At the time of medical record review, 17 patients were deceased with a median survival of 8.3 (IQR = 7, 10.9) years. Univariate analysis showed that initial onset of autonomic failure predicted unfavorable survival (hazard ratio = 2.89, P = 0.04) compared to those who presented with motor impairment only at onset. At the time of YOMSA diagnosis, composite autonomic severity score was available in 19 patients with a median of 5 (IQR = 4, 6.5).
Conclusions
YOMSA resembles MSA in most aspects including phenotype and prognosis, although the diagnosis is usually delayed. The presence of autonomic failure at symptom onset may be a poor predictor for survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona, USA.
- Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Negin Badihian, Rodolfo Savica, Charles H Adler, Zbigniew K Wszolek, Wolfgang Singer, Elizabeth A Coon
Förderung
- NIH HHS
- NCATS NIH HHS
- FDA HHS
- NINDS NIH HHS
- Food and Drug Administration
- Mayo Clinic
- National Institutes of Health
Zitieren
APA
Badihian, N., Savica, R., Adler, C. H., Wszolek, Z. K., Jackson, L. M., Benarroch, E. E., Sandroni, P., Low, P. A., Singer, W., & Coon, E. A. (2024). Clinical Characteristics and Outcomes in Young‐Onset Multiple System Atrophy. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.13925
Vancouver
Badihian N, Savica R, Adler CH, Wszolek ZK, Jackson LM, Benarroch EE, et al. Clinical Characteristics and Outcomes in Young‐Onset Multiple System Atrophy. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.13925
BibTeX
@article{Badihian2024,
author = {Badihian, Negin and Savica, Rodolfo and Adler, Charles H and Wszolek, Zbigniew K and Jackson, Lauren M and Benarroch, Eduardo E and Sandroni, Paola and Low, Phillip A and Singer, Wolfgang and Coon, Elizabeth A},
title = {Clinical Characteristics and Outcomes in Young‐Onset Multiple System Atrophy},
journal = {Movement Disorders Clinical Practice},
year = {2024},
doi = {10.1002/mdc3.13925}
}
EUVIMED